| Dr Vijay S Suhag, MD | |
|
11795 Education Street, Suite 232, Auburn, CA 95602-2454 | |
| (530) 886-6587 | |
| (530) 886-6586 |
| Full Name | Dr Vijay S Suhag |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 23 Years |
| Location | 11795 Education Street, Auburn, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063682433 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | A 102352 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sutter Visiting Nurse Association And Hospice | Roseville, CA | Hospice |
| Sutter Medical Center, Sacramento | Sacramento, CA | Hospital |
| Sutter Roseville Medical Center | Roseville, CA | Hospital |
| Sutter Auburn Faith Hospital | Auburn, CA | Hospital |
| Sutter Amador Hospital | Jackson, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sutter Valley Medical Foundation | 9830094515 | 1840 |
News Archive
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced the initiation of two clinical studies of TC-5619, a Phase 2b study evaluating the product candidate as a treatment for negative symptoms and cognitive dysfunction in schizophrenia and a Phase 2 study evaluating the product candidate in adults as a treatment for attention deficit/hyperactivity disorder (ADHD), inattentive-predominant.
Pharmos Corporation today reported financial results for the third quarter and nine-month period ended September 30, 2009.
Researchers at Boston University School of Medicine (BUSM) have found that pediatricians provided with the proper communication, educational and information technology tools and training could reduce the rates of children developing early childhood caries (ECC) or cavities by 77 percent. This study appears in the October issue of the Journal Medical Care.
Research into intermittent preventive treatment of malaria in infants (IPTi) found that one-third of malaria cases in African babies can be prevented by giving them regular doses of malaria drugs even if they have not contracted the disease, according to a Lancet study, published on Thursday, Reuters reports. The study found that IPTi "helped children build better immunity to the disease and reduced the risk of the parasite becoming drug-resistant," but "these benefits decrease if treatment is given continuously as a prophylaxis," Reuters writes.
› Verified 7 days ago
| Entity Name | Sutter Valley Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669846986 PECOS PAC ID: 9830094515 Enrollment ID: O20090311000335 |
News Archive
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced the initiation of two clinical studies of TC-5619, a Phase 2b study evaluating the product candidate as a treatment for negative symptoms and cognitive dysfunction in schizophrenia and a Phase 2 study evaluating the product candidate in adults as a treatment for attention deficit/hyperactivity disorder (ADHD), inattentive-predominant.
Pharmos Corporation today reported financial results for the third quarter and nine-month period ended September 30, 2009.
Researchers at Boston University School of Medicine (BUSM) have found that pediatricians provided with the proper communication, educational and information technology tools and training could reduce the rates of children developing early childhood caries (ECC) or cavities by 77 percent. This study appears in the October issue of the Journal Medical Care.
Research into intermittent preventive treatment of malaria in infants (IPTi) found that one-third of malaria cases in African babies can be prevented by giving them regular doses of malaria drugs even if they have not contracted the disease, according to a Lancet study, published on Thursday, Reuters reports. The study found that IPTi "helped children build better immunity to the disease and reduced the risk of the parasite becoming drug-resistant," but "these benefits decrease if treatment is given continuously as a prophylaxis," Reuters writes.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Vijay S Suhag, MD 10470 Old Placerville Rd, Suite 100, Sacramento, CA 95827-2539 Ph: (800) 470-0071 | Dr Vijay S Suhag, MD 11795 Education Street, Suite 232, Auburn, CA 95602-2454 Ph: (530) 886-6587 |
News Archive
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced the initiation of two clinical studies of TC-5619, a Phase 2b study evaluating the product candidate as a treatment for negative symptoms and cognitive dysfunction in schizophrenia and a Phase 2 study evaluating the product candidate in adults as a treatment for attention deficit/hyperactivity disorder (ADHD), inattentive-predominant.
Pharmos Corporation today reported financial results for the third quarter and nine-month period ended September 30, 2009.
Researchers at Boston University School of Medicine (BUSM) have found that pediatricians provided with the proper communication, educational and information technology tools and training could reduce the rates of children developing early childhood caries (ECC) or cavities by 77 percent. This study appears in the October issue of the Journal Medical Care.
Research into intermittent preventive treatment of malaria in infants (IPTi) found that one-third of malaria cases in African babies can be prevented by giving them regular doses of malaria drugs even if they have not contracted the disease, according to a Lancet study, published on Thursday, Reuters reports. The study found that IPTi "helped children build better immunity to the disease and reduced the risk of the parasite becoming drug-resistant," but "these benefits decrease if treatment is given continuously as a prophylaxis," Reuters writes.
› Verified 7 days ago
Dr. Frances Fua Canet, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3288 Bell Rd, Auburn, CA 95603 Phone: 530-745-0700 Fax: 530-745-0701 | |
Mrs. Dana Ciobanu, D.O Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 11815 Education St, Auburn, CA 95602 Phone: 530-886-6558 | |
Dr. Danny Yen, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 11795 Education St Ste 201, Auburn, CA 95602 Phone: 530-886-6800 Fax: 530-886-6801 | |
Mihaela M Hasse, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 11670 Atwood Road, Auburn, CA 95603 Phone: 530-889-8336 | |
Sujata Narayanan, M.D Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 11815 Education Street, Auburn, CA 95602 Phone: 530-886-6558 Fax: 530-889-6035 | |
Apeet Hundal, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3111 Professional Dr, Auburn, CA 95603 Phone: 530-885-5618 |